MA54009B1 - Formulation d'afabicine et son procédé de préparation - Google Patents
Formulation d'afabicine et son procédé de préparationInfo
- Publication number
- MA54009B1 MA54009B1 MA54009A MA54009A MA54009B1 MA 54009 B1 MA54009 B1 MA 54009B1 MA 54009 A MA54009 A MA 54009A MA 54009 A MA54009 A MA 54009A MA 54009 B1 MA54009 B1 MA 54009B1
- Authority
- MA
- Morocco
- Prior art keywords
- afabicin
- formulation
- preparation
- compositions
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des compositions pharmaceutiques solides contenant de l'afabicine présentant des caractéristiques supérieures de dissolution. Cet effet bénéfique est accompli par la présence d'un composé histidine pour la fabrication des compositions. La présente invention concerne en outre des procédés de préparation de telles compositions et des utilisations associées.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19157255 | 2019-02-14 | ||
PCT/EP2020/053882 WO2020165407A1 (fr) | 2019-02-14 | 2020-02-14 | Formulation d'afabicine et son procédé de préparation |
Publications (2)
Publication Number | Publication Date |
---|---|
MA54009A1 MA54009A1 (fr) | 2022-05-31 |
MA54009B1 true MA54009B1 (fr) | 2022-10-31 |
Family
ID=65440901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA54009A MA54009B1 (fr) | 2019-02-14 | 2020-02-14 | Formulation d'afabicine et son procédé de préparation |
Country Status (27)
Country | Link |
---|---|
US (1) | US20220142993A1 (fr) |
EP (1) | EP3923914B1 (fr) |
JP (1) | JP7383715B2 (fr) |
KR (1) | KR20210127187A (fr) |
CN (2) | CN116327781A (fr) |
AU (1) | AU2020223515A1 (fr) |
BR (1) | BR112021015825B1 (fr) |
CA (1) | CA3129508A1 (fr) |
CL (1) | CL2021002149A1 (fr) |
CY (1) | CY1126077T1 (fr) |
DK (1) | DK3923914T3 (fr) |
EA (1) | EA202192246A1 (fr) |
ES (1) | ES2944535T3 (fr) |
FI (1) | FI3923914T3 (fr) |
HR (1) | HRP20230437T1 (fr) |
HU (1) | HUE062061T2 (fr) |
IL (1) | IL285204A (fr) |
LT (1) | LT3923914T (fr) |
MA (1) | MA54009B1 (fr) |
MX (1) | MX2021009799A (fr) |
PL (1) | PL3923914T3 (fr) |
PT (1) | PT3923914T (fr) |
RS (1) | RS64158B1 (fr) |
SG (1) | SG11202108591PA (fr) |
SI (1) | SI3923914T1 (fr) |
TN (1) | TN2021000159A1 (fr) |
WO (1) | WO2020165407A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022515775A (ja) | 2018-12-21 | 2022-02-22 | アクルクス ファーマシューティカルズ エルエルシー | Dnaポリメラーゼiiic阻害剤及びその使用 |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2444597A1 (fr) | 2001-04-06 | 2002-10-06 | Affinium Pharmaceuticals, Inc. | Inhibiteurs de fab i |
CN101415701A (zh) * | 2005-12-05 | 2009-04-22 | Affinium医药公司 | 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂 |
JP6085026B2 (ja) | 2012-06-19 | 2017-02-22 | デビオファーム インターナショナル エスエーDebiopharm International Sa | (e)−n−メチル−n−((3−メチルベンゾフラン−2−イル)メチル)−3−(7−オキソ−5,6,7,8−テトラヒドロ−1,8−ナフチリジン−3−イル)アクリルアミドのプロドラッグ誘導体 |
CA3014541A1 (fr) * | 2016-02-26 | 2017-08-31 | Debiopharm International S.A. | Medicament pour le traitement des infections du pied diabetique |
-
2020
- 2020-02-14 LT LTEPPCT/EP2020/053882T patent/LT3923914T/lt unknown
- 2020-02-14 AU AU2020223515A patent/AU2020223515A1/en active Pending
- 2020-02-14 HU HUE20704307A patent/HUE062061T2/hu unknown
- 2020-02-14 ES ES20704307T patent/ES2944535T3/es active Active
- 2020-02-14 RS RS20230315A patent/RS64158B1/sr unknown
- 2020-02-14 EA EA202192246A patent/EA202192246A1/ru unknown
- 2020-02-14 SG SG11202108591PA patent/SG11202108591PA/en unknown
- 2020-02-14 EP EP20704307.6A patent/EP3923914B1/fr active Active
- 2020-02-14 MX MX2021009799A patent/MX2021009799A/es unknown
- 2020-02-14 HR HRP20230437TT patent/HRP20230437T1/hr unknown
- 2020-02-14 MA MA54009A patent/MA54009B1/fr unknown
- 2020-02-14 PL PL20704307.6T patent/PL3923914T3/pl unknown
- 2020-02-14 CN CN202310544746.8A patent/CN116327781A/zh active Pending
- 2020-02-14 KR KR1020217028702A patent/KR20210127187A/ko unknown
- 2020-02-14 JP JP2021545458A patent/JP7383715B2/ja active Active
- 2020-02-14 CA CA3129508A patent/CA3129508A1/fr active Pending
- 2020-02-14 WO PCT/EP2020/053882 patent/WO2020165407A1/fr active Application Filing
- 2020-02-14 BR BR112021015825-1A patent/BR112021015825B1/pt active IP Right Grant
- 2020-02-14 FI FIEP20704307.6T patent/FI3923914T3/fi active
- 2020-02-14 TN TNP/2021/000159A patent/TN2021000159A1/en unknown
- 2020-02-14 CN CN202080014005.3A patent/CN113423390B/zh active Active
- 2020-02-14 DK DK20704307.6T patent/DK3923914T3/da active
- 2020-02-14 SI SI202030183T patent/SI3923914T1/sl unknown
- 2020-02-14 PT PT207043076T patent/PT3923914T/pt unknown
- 2020-02-14 US US17/430,616 patent/US20220142993A1/en active Pending
-
2021
- 2021-07-28 IL IL285204A patent/IL285204A/en unknown
- 2021-08-13 CL CL2021002149A patent/CL2021002149A1/es unknown
-
2023
- 2023-05-09 CY CY20231100220T patent/CY1126077T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK3923914T3 (da) | 2023-05-01 |
FI3923914T3 (fi) | 2023-04-27 |
CA3129508A1 (fr) | 2020-08-20 |
LT3923914T (lt) | 2023-07-25 |
CY1126077T1 (el) | 2023-11-15 |
WO2020165407A1 (fr) | 2020-08-20 |
RS64158B1 (sr) | 2023-05-31 |
ES2944535T3 (es) | 2023-06-22 |
SG11202108591PA (en) | 2021-09-29 |
SI3923914T1 (sl) | 2023-08-31 |
PL3923914T3 (pl) | 2023-08-07 |
MX2021009799A (es) | 2021-09-08 |
AU2020223515A1 (en) | 2021-08-19 |
CL2021002149A1 (es) | 2022-03-04 |
HUE062061T2 (hu) | 2023-09-28 |
CN116327781A (zh) | 2023-06-27 |
EP3923914A1 (fr) | 2021-12-22 |
US20220142993A1 (en) | 2022-05-12 |
CN113423390B (zh) | 2023-05-23 |
MA54009A1 (fr) | 2022-05-31 |
BR112021015825B1 (pt) | 2024-03-12 |
BR112021015825A2 (pt) | 2021-10-13 |
KR20210127187A (ko) | 2021-10-21 |
HRP20230437T1 (hr) | 2023-07-07 |
IL285204A (en) | 2021-09-30 |
CN113423390A (zh) | 2021-09-21 |
JP2022520170A (ja) | 2022-03-29 |
EP3923914B1 (fr) | 2023-04-12 |
EA202192246A1 (ru) | 2021-11-18 |
TN2021000159A1 (en) | 2023-04-04 |
JP7383715B2 (ja) | 2023-11-20 |
PT3923914T (pt) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54009A1 (fr) | Formulation d'afabicine et son procédé de préparation | |
MA30762B1 (fr) | Anticorps specifiques du prlr et leurs utilisations | |
MA42811B1 (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
FR2525205A1 (fr) | Composition biocide a base d'isothiazolone et de glutaraldehyde et procede pour le traitement d'eau de refroidissement ou d'eau utilisee dans la fabrication du papier | |
MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
MA31684B1 (fr) | Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation | |
MA45972B1 (fr) | Unité posologique orodispersible contenant un composant d'estétrol | |
MA44205A (fr) | Comprimé orodispersible comprenant estetrol | |
MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
WO2019207257A8 (fr) | Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices | |
MA41494A (fr) | Composés benzoxaborole substitués en position 4 et utilisations associées | |
MX2022007275A (es) | Composiciones de acidos biliares y compuestos de fenilbutirato. | |
FR3086943B1 (fr) | Copolymere d'ethylene et de beta-farnesene | |
MA30523B1 (fr) | Compose tricylique et utilisation pharmaceutique de celui-ci | |
MA41174B1 (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta | |
MA57000B1 (fr) | Dérivés d'alpha-d-galactopyranoside | |
FR3100723B1 (fr) | Procédé de préparation d’atomes métalliques isolés ou d’un mélange d’atomes métalliques isolés et de nanoparticules métalliques sur matériau carboné | |
CA2473203A1 (fr) | Composition pharmaceutique orodispersible d'ivabradine | |
CH668190A5 (fr) | Pastilles effervescentes chlorees a usage de desinfection. | |
MA34054B1 (fr) | Bromhydrate d'agomelatine hydrate et sa preparation | |
FR3105787B1 (fr) | Procede de preparation de particules d’oxyde de zinc enrobees par pyrolyse par projection de flamme | |
MA53043A1 (fr) | Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation | |
CA3156074A1 (fr) | Inhibiteurs de mll1 et agents anticancereux | |
US2614918A (en) | Method of setting fruit and composition therefor | |
FR2403798A1 (fr) | Compositions synergiques a base de disulfure de bis(2-pyridyl-1-oxyde et leur utilisation pour leur activite anti-inflammatoire |